No Prognostic Impact of p53 and P-Glycoprotein Expression in Patients with Diffuse Large B-Cell Lymphoma
Open Access
- 22 December 2011
- journal article
- Published by Wiley in ISRN Oncology
- Vol. 2011, 1-6
Abstract
The aim of this study was to determine the clinical significances of p53 and p-glycoprotein (P-gp) expression on outcome predictors for patients with DLBC. We assessed the immunohistochemical expression of p53 and P-gp using formalin-fixed, paraffin-embedded specimens in 108 patients diagnosed with de novo DLBC. A high expression of p53 was found in 53.7% of the patients. No expression of P-gp was demonstrated in any of the specimens. There were no significant differences in the complete remission (CR) rate (), overall survival (OS) (), or disease-free survival (DFS) () between the p53-positive and p53-negative groups. The final model from multivariate analysis that revealed poor performance status was significantly associated with CR () and OS (). Moreover, the advanced stage was a significant predictor of DFS (). This study demonstrated no impact of the expression of p53 on either response or survival rates.
Keywords
Funding Information
- Prince of Songkla University
This publication has 22 references indexed in Scilit:
- Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphomaInternational Journal of Oncology, 2011
- Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non‐germinal centre B‐like diffuse large B‐cell lymphomasHistopathology, 2005
- Immunohistochemical Expression of Multidrug Resistance Proteins as a Predictor of Poor Response to Chemotherapy and Prognosis in Patients with Nodal Diffuse Large B-Cell LymphomaOncology, 2005
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphomaBlood, 2003
- The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Expression of c-Myc and p53 Correlates With Clinical Outcome in Diffuse Large B-Cell LymphomasAmerican Journal of Clinical Pathology, 2000
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stressOncogene, 1998